| 2024 | Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer | CANCER RESEARCH |
| 2023 | Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer
| GLAND SURGERY |
| 2023 | Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045 | INTERNATIONAL JOURNAL OF CANCER |
| 2023 | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
| PLOS ONE |
| 2023 | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | JAMA SURGERY |
| 2023 | Comparison of Single-Port Laparoscopy with Other Surgical Approaches in Endometrial Cancer Surgical Staging: Propensity-Score-Matched Analysis
| CANCERS |
| 2023 | Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer | BRITISH JOURNAL OF CANCER |
| 2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2023 | Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC)
| BMC CANCER |
| 2023 | Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
| NATURE COMMUNICATIONS |
| 2023 | Comparison of oncological outcomes between sentinel lymph node biopsy and complete lymphadenectomy for endometrial cancer | JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH |
| 2023 | Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer | CLINICAL CANCER RESEARCH |
| 2023 | Comparing surgical outcomes of da Vinci SP and da Vinci Xi for endometrial cancer surgical staging in a propensity score-matched study
| SCIENTIFIC REPORTS |
| 2023 | RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Sentinel lymph node biopsy in endometrial cancer: The new norm - A multicentre, international experience | SURGICAL ONCOLOGY-OXFORD |
| 2023 | CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy | CLINICAL CANCER RESEARCH |
| 2023 | Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer
| FRONTIERS IN ONCOLOGY |
| 2023 | BNT162b2 접종과 면역관문억제제 치료 이후 발생한 이상 반응 1예
| Korean Journal of Medicine |
| 2023 | Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2022 | USEFULNESS OF PRE-OPERATIVE PET-CT IN PATIENTS WITH ENDOMETRIAL CANCER UNDERGOING SENTINEL LYMPH NODE MAPPING: DO NEGATIVE FINDINGS ON PET-CT NEGATIVITY REALLY INDICATE NODE NEGATIVITY? | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | ROBOTIC-ASSISTED RADICAL VAGINAL TRACHELECTOMY | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | RE-VALIDATION OF CHEMOTHERAPY RESPONSE SCORE (CRS) AS A PROGNOSTIC FACTOR IN OVARIAN CANCER: THE EFFECT OF BEVACIZUMAB AND HIPEC ON SURVIVAL | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | PROSPECTIVE MULTI-INSTITUTIONAL PHASE III TRIAL OF STANDARD OF CARE THERAPY WITH OR WITHOUT STEROTACTIC ABLATIVE RADIATION THERAPY FOR RECURRENT OVARIAN CANCER (SABR-ROC, KGOG 3064/KROG 2204) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | PROPENSITY SCORE-MATCHED COMPARISON OF PERIOPERATIVE OUTCOMES USING DA VINCI XI AND SP SURGICAL SYSTEM IN ENDOMETRIAL CANCER SURGICAL STAGING | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | PREDICTION OF SURGICAL OUTCOMES OF INTERVAL DEBULKING SURGERY (IDS) USING IN ADVANCED OVARIAN CANCER: A NOVEL SCORING SYSTEM USING POST-NEOADJUVANT CHEMOTHERAPY (NAC) COMPUTED TOMOGRAPHY (CT) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | PATIENT-DERIVED ORGANOIDS AS A PRECLINICAL PLATFORM FOR PRECISION MEDICINE IN PATIENTS WITH CERVICAL CANCER | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | OREGOVOMAB AND NON-PLATINUM SINGLE AGENT CHEMOTHERAPY IN PARP INHIBITOR-RESISTANT OVARIAN CANCER PATIENTS NOT CANDIDATE FOR PLATINUM RETREATMENT: A MULTI-COHORT PHASE II STUDY (KGOG 3065/APGOT-OV6) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | LATE-BREAKING ABSTRACT PRESENTATION: COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | LAPAROSCOPIC LEFT COMMON ILIAC VEIN INJURY AND REPAIR | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | IMMUNE PROPERTIES OF TUMOR-INFILTRATING LYMPHOCYTES IN OVARIAN CLEAR CELL CARCINOMA RELATIVE TO OVARIAN HIGH-GRADE SEROUS CARCINOMA | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2) RECEPTOR EXPRESSION AND ITS DYNAMIC CHANGE IN OVARIAN CANCER PATIENTS | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Dynamic changes of peripheral regulatory t cells during parp inhibitor maintenance therapy in patients with ovarian cancer | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Comprehensive profiling of cervix cancer patients using tumor next-generation sequencing (NGS) and immunohistochemistry (IHC) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | An open label, single arm, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16 or 18 positive recurrent cervical cancer
| INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Added value of sentinel lymph node biopsy in patients with negative lymph node on triple pre-operative images | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
| GYNECOLOGIC ONCOLOGY |
| 2022 | Usefulness and potential pitfalls of pre-operative PET-CT in patients with endometrial cancer undergoing one- and two-step sentinel lymph node mapping: Do negative findings on PET-CT negativity really indicate node negativity? | GYNECOLOGIC ONCOLOGY |
| 2022 | Feasibility and clinical applicability of genomic profiling based on cervical smear samples in patients with endometrial cancer
| FRONTIERS IN ONCOLOGY |
| 2022 | Identification of Lynch Syndrome in Patients with Endometrial Cancer Based on a Germline Next Generation Sequencing Multigene Panel Test
| CANCERS |
| 2022 | Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
| FRONTIERS IN ONCOLOGY |
| 2022 | Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2022 | A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)
| IN VIVO |
| 2022 | PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2022 | Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2022 | Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea | GYNECOLOGIC ONCOLOGY |
| 2022 | Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer
| CANCERS |
http://orcid.org/0000-0001-7948-1350
(56191369600)
